2020
DOI: 10.1016/j.biopsych.2019.05.026
|View full text |Cite
|
Sign up to set email alerts
|

Translating Opioid Pharmacology From Bench to Bedside, and Back

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 12 publications
(12 reference statements)
0
1
0
Order By: Relevance
“…This risk is particularly acute in countries where fentanyl is readily available: e.g., drug deaths have recently exceeded 100,000/year in the USA being further exacerbated by the COVID-19 pandemic [ 51 , 52 ]. Our findings also highlight the importance of the NVS as a target for new OUD treatments (e.g., partial MOR1 agonism, k-type opioid receptor antagonism, and α-2A adrenergic receptor agonism) [ 53 , 54 ].…”
Section: Discussionmentioning
confidence: 78%
“…This risk is particularly acute in countries where fentanyl is readily available: e.g., drug deaths have recently exceeded 100,000/year in the USA being further exacerbated by the COVID-19 pandemic [ 51 , 52 ]. Our findings also highlight the importance of the NVS as a target for new OUD treatments (e.g., partial MOR1 agonism, k-type opioid receptor antagonism, and α-2A adrenergic receptor agonism) [ 53 , 54 ].…”
Section: Discussionmentioning
confidence: 78%